The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000696392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
21/05/2026
Date registered
Help: Date registered
11/06/2026
Date last updated
Help: Date last updated
20/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
11/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Corneal immune cell dynamics in low-level light therapy
Scientific title
Investigating corneal immune cell features in low level light therapy with different coloured light in adults with dry eye disease and Meibomian gland dysfunction
Additional trial identifiers [1] 316691 0
Nil known
Universal Trial Number (UTN)
U1111-1340-1612
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Dry eye disease 340940 0
Meibomian gland dysfunction 340941 0
Condition category
Condition code
Eye 337092 337092 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The study interventions comprise low-level light therapy delivered via a clinical device (Eye-light, Espansione Group, Italy) used for treating dry eye. This device is TGA-approved (ARTG listing number 326014), and intended for the treatment of dry eye syndrome by targeting the meibomian glands around the eyelids. Facial masks, which contain a series of light emitting diodes (LEDs), are used to deliver the treatment in-office for 15 minutes over a course of four visits, each 7±3 days apart. Participants will be seated or lying down comfortably for the duration of the treatment.

Participants will be randomised into one of three treatment groups (red light therapy [633 nm wavelength], blue light therapy [428 nm wavelength], and inactive control therapy [sham red or sham blue light]). A researcher not involved with performing the clinical assessments will develop a randomisation schedule using a randomisation table created by computer software (i.e., computerised sequence generation) for the study intervention (1:1:1), and also a separate randomisation (1:1) sub-schedule for sham red or sham blue light intervention for those sub-randomised to the inactive control therapy group. The randomisation schedules will be concealed in sealed envelopes until a study researcher designated as a treatment administrator unseals the envelope before the first treatment at Visit 2. A session attendance checklist will be used to monitor exposure to intervention for each participant.

Corneal imaging will also be done immediately after the first treatment (Visit 2) to assess for the short-term impact(s) of low-level light therapy, and before the second treatment (Visit 3), third treatment (Visit 4) and fourth treatment (Visit 5) to assess the longitudinal effects of a course of treatment. A 1-month post-treatment follow-up visit (Visit 6) will also be conducted to assess for any potential extended impacts.
Intervention code [1] 333372 0
Treatment: Devices
Description of the comparator or control
Sham red or sham blue light facial masks, made by the manufacturer (Espansione Group, Italy) and identical in physical design to the active intervention, will be used as an inactive control therapy (having <10% full energy output) to act as a comparator. The inactive control therapy will be delivered for 15 minutes over a course of four visits, each 7±3 days apart. Participants will be seated or lying down comfortably for the duration of the treatment.
Control group
Placebo

Outcomes
Primary outcome [1] 344613 0
Inter-group difference in the change from baseline (Visit 1) to the 1-month post-treatment follow up (Visit 6) in the in vivo mean instantaneous speed of putative corneal T cells between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [1] 344613 0
Baseline and 1-month post-treatment follow up (Visit 6).
Secondary outcome [1] 458605 0
Inter-group difference in change from baseline (Visit 1) to after the first treatment (Visit 2), before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) to the density of corneal immune cell subsets (except for mean instantaneous speed of T cells at Visit 6), at the whorl and inferior cornea, between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [1] 458605 0
Baseline, and after the first treatment (Visit 2), before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [2] 458606 0
Inter-group difference in change from baseline (Visit 1) to after the first treatment (Visit 2), before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) to the density of corneal immune cell subsets at the central cornea, between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [2] 458606 0
Baseline, and after the first treatment (Visit 2), before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [3] 458607 0
Inter-group difference in change from baseline (Visit 1) to after the first treatment (Visit 2), before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) to corneal cell-to-cell interactions (e.g., proportion of T cell-dendritic cell contacts), at the whorl and inferior cornea, between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [3] 458607 0
Baseline, and after the first treatment (Visit 2), before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [4] 458608 0
Inter-group difference in change from baseline (Visit 1) to after the first treatment (Visit 2), before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) to corneal neuroimmune features (e.g. T cell speed - before and after apparent nerve interaction), at the whorl and inferior cornea, between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [4] 458608 0
Baseline, and after the first treatment (Visit 2), before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [5] 458609 0
Exploratory outcome [1]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in tear pro-inflammatory cytokine levels between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [5] 458609 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [6] 458610 0
Exploratory outcome [2]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in tear rheology parameters between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [6] 458610 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [7] 458611 0
Exploratory outcome [3]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in clinical parameters of dry eye and MGD, including symptom scores from the Ocular Surface Disease Index [OSDI] questionnaire.
Timepoint [7] 458611 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [8] 458612 0
Exploratory outcome [4]: Inter-group difference in change from baseline (Visit 1) at the 1-month post-treatment follow up (Visit 6) in tear osmolarity between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [8] 458612 0
Baseline and 1-month post-treatment follow up (Visit 6).
Secondary outcome [9] 458618 0
Exploratory outcome [5]: Inter-group difference in change from just before the first treatment to immediately after the first treatment (at Visit 2) in rate of temperature change of the cornea between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [9] 458618 0
Just before the first treatment and immediately after the first treatment (at Visit 2).
Secondary outcome [10] 460958 0
Exploratory outcome [6]: Inter-subgroup difference in change from baseline (Visit 1) to after the first treatment (Visit 2), before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) to corneal immune cell features between sham red and sham blue light.
Timepoint [10] 460958 0
Baseline, and after the first treatment (Visit 2), before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [11] 461054 0
Exploratory outcome [7]: Inter-subgroup difference in change from baseline (Visit 1) to after the first treatment (Visit 2), before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) to corneal immune cell features between red light therapy and sham red light.
Timepoint [11] 461054 0
Baseline, and after the first treatment (Visit 2), before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [12] 461056 0
Exploratory outcome [8]: Inter-subgroup difference in change from baseline (Visit 1) to after the first treatment (Visit 2), before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) to corneal immune cell features between blue light therapy and sham blue light.
Timepoint [12] 461056 0
Baseline, and after the first treatment (Visit 2), before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [13] 462374 0
Inter-group difference in change from baseline (Visit 1) to after the first treatment (Visit 2), before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) to the morphology of corneal immune cell subsets (except for mean instantaneous speed of T cells at Visit 6), at the whorl and inferior cornea, between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [13] 462374 0
Baseline, and after the first treatment (Visit 2), before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [14] 462375 0
Inter-group difference in change from baseline (Visit 1) to after the first treatment (Visit 2), before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) to the dynamics of corneal immune cell subsets (except for mean instantaneous speed of T cells at Visit 6), at the whorl and inferior cornea, between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [14] 462375 0
Baseline, and after the first treatment (Visit 2), before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [15] 462376 0
Inter-group difference in change from baseline (Visit 1) to after the first treatment (Visit 2), before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) to corneal cell-to-cell interactions (e.g., duration of T cell-dendritic cell contacts), at the whorl and inferior cornea, between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [15] 462376 0
Baseline, and after the first treatment (Visit 2), before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [16] 462377 0
Inter-group difference in change from baseline (Visit 1) to after the first treatment (Visit 2), before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) to corneal neuroimmune features (e.g. the proportion of T cells observed to contact nerves), at the whorl and inferior cornea, between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [16] 462377 0
Baseline, and after the first treatment (Visit 2), before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [17] 462378 0
Exploratory outcome [9]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in tear pro-inflammatory chemokine levels between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [17] 462378 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [18] 462379 0
Exploratory outcome [10]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in clinical parameters of dry eye and MGD, including symptom scores from the Ocular Surface Disease Index (OSDI)-6 questionnaire.
Timepoint [18] 462379 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [19] 462380 0
Exploratory outcome [11]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in clinical parameters of dry eye and MGD, including tear meniscus height [TMH].
Timepoint [19] 462380 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [20] 462381 0
Exploratory outcome [12]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in clinical parameters of dry eye and MGD, including non-invasive tear break up time [NITBUT].
Timepoint [20] 462381 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [21] 462382 0
Exploratory outcome [13]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in clinical parameters of dry eye and MGD, including bulbar conjunctival hyperaemia.
Timepoint [21] 462382 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [22] 462383 0
Exploratory outcome [14]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in clinical parameters of dry eye and MGD, including corneal staining.
Timepoint [22] 462383 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [23] 462384 0
Exploratory outcome [15]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in clinical parameters of dry eye and MGD, including conjunctival staining.
Timepoint [23] 462384 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [24] 462385 0
Exploratory outcome [16]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in clinical parameters of dry eye and MGD, including lid wiper epitheliopathy.
Timepoint [24] 462385 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [25] 462386 0
Exploratory outcome [17]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in clinical parameters of dry eye and MGD, including meibomian gland secretion [MGS] score.
Timepoint [25] 462386 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [26] 462387 0
Exploratory outcome [18]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in clinical parameters of dry eye and MGD, including meibomian gland yielding liquid secretion [MGYLS] score.
Timepoint [26] 462387 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).
Secondary outcome [27] 462388 0
Exploratory outcome [19]: Inter-group difference in change from baseline (Visit 1) at the 1-month post-treatment follow up (Visit 6) in meibography between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [27] 462388 0
Baseline and 1-month post-treatment follow up (Visit 6).
Secondary outcome [28] 462389 0
Exploratory outcome [20]: Inter-group difference in change from just before the first treatment to immediately after the first treatment (at Visit 2) in mean temperature of the cornea between red light therapy, blue light therapy and inactive control therapy (sham red or sham blue light).
Timepoint [28] 462389 0
Just before the first treatment and immediately after the first treatment (at Visit 2).
Secondary outcome [29] 465336 0
Exploratory outcome [21]: Inter-group difference in change from baseline (Visit 1) to before the second, third and fourth treatments (Visits 3 to 5), and at the 1-month post-treatment follow up (Visit 6) in clinical parameters of dry eye and MGD, including lid margin telangiectasia.
Timepoint [29] 465336 0
Baseline, before the second treatment (Visit 3), before the third treatment (Visit 4), before the fourth treatment (Visit 5), and at the 1-month post-treatment follow up (Visit 6).

Eligibility
Key inclusion criteria
Participant inclusion criteria at the screening evaluation visit (Visit 1):
1. Male or female aged at least 18, with full legal capacity to volunteer;
2. Provide written informed consent to participate;
3. Can understand and follow study instructions, with the intention of completing all required study visits;
4. Have typical sleeping patterns, defined generally as obtaining at least 6 hours of sleep per night, with sleep onset time between 21:00 PM and 2:00 AM, and waking up between 05:00 AM and 09:00 AM, by self-report;
5. Have at least 3 T cells in either the whorl or inferior cornea within the imaging field of view on in vivo confocal microscopy (IVCM);
6. Be sufficiently proficient in English to understand the study details, instructions, and answer questions from the study researcher, and the study questionnaires;
7. Has not worn contact lenses consistently (i.e., more than once per week) over the 3 months prior, and not anticipated throughout their participation in the study;
8. Has clinically significant dry eye disease, as defined by the TFOS DEWS III definition, involve dry eye symptoms (i.e., an Ocular Surface Disease Index (OSDI) [full version] score greater than or equal to 13, out of 100, AND at least one of the following clinical signs:
a. Tear osmolarity of more than or equal to 308 mOsm/L in either eye or an interocular difference greater than 8 mOsm/L;
b. NITBUT < 10 sec in either eye;
c. Ocular surface staining: > 5 corneal spots with fluorescein, > 9 conjunctival spots with lissamine green, or eyelid margin staining (more than or equal to 2 mm length and more than or equal to 25% width) with lissamine green
9. Has meibomian gland dysfunction (MGD), defined by a meibomian gland score (MGS) of less than or equal to 12.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion criteria at the screening evaluation visit (Visit 1):
1. Any active ocular disease and/or infection (besides dry eye disease and MGD) that might significantly affect corneal immune cells or nerves;
2. A clinically significant injury to either eye in the past 12 weeks;
3. Ocular surgery within the past six months, or ocular surgery is planned over the course of participation in the study;
4. Prior history of laser refractive eye surgery;
5. A known allergy to, or previous reaction to, any eye drops required for the study;
6. The presence of cancer in the required treatment area for the low-level light therapy (e.g. basal cell carcinoma, squamous cell carcinoma and/or melanoma of the facial skin);
7. Photosensitivity to red or blue light, or a history of light-induced nervous system disorders such as epilepsy or migraine, by self-report;
8. Current use of photosensitising medications (such as doxycycline, Roaccutane), or anticipated use over the course of participation in the study, by self-report;
9. Presence of non-removable metallic piercings in the periocular and malar regions;
10. Unwilling to avoid wearing excessive make-up, eyelash extensions or removable metallic piercings at the treatment area to avoid interference with the light therapy during treatment sessions (at Visit 2, Visit 3, Visit 4 and Visit 5);
10. Presence of significant corneal scarring or a physical factor that impairs the ability to perform corneal imaging;
11. Current or recent use (within the last 30 days) of any topical medications other than artificial lubricant eye drops (e.g., anti-allergy eye drops, anti-glaucoma medications, corticosteroids) or systemic corticosteroids or immunomodulatory medications, or anticipated use over the course of participation in the study;
12. Anticipated change in non-heat based, self-administered eyelid hygiene regimen over the course of the study (Note: Participants must have had a stable regimen for at least 30 days prior to Visit 1), by self-report;
13. A history of using warm eye compresses 30 days prior, or anticipated use over the course of participation in the study, by self-report;
14. A history of receiving Lipiflow or similar treatments, or light-based therapies including intense pulsed light therapy and low-level light therapy, on the facial regions within 6 months prior, or anticipated use over the course of participation in the study, by self-report;
15. A history of a systemic infection known to affect corneal immune status (e.g., positive for COVID-19 or upper respiratory infection within the past four weeks), by self-report;
16. A systemic condition (e.g., Sjogren’s disease, diabetes or other) that affects corneal immune status;
17. Has received a vaccination in the past two weeks, by self-report;
18. An infectious blood-borne illness, such as hepatitis or human immunodeficiency virus (HIV), that may affect the eyes, by self-report;
19. Females who are pregnant or breastfeeding, or who plan to become pregnant during the study, by self-report;
20. Unable to sit/lie supine comfortably during the examination procedures;
21. Participation in an interventional clinical trial within the previous 30 days, or currently enrolled in an interventional clinical trial;
22. Current shiftwork and/or recent cross-time zone travel in the last month, or such anticipated travel during the study period;
23. A condition or situation that, in the opinion of the study investigator, will limit the potential participant’s ability to comply with the study protocol, might adversely affect their safety or substantially confound the study outcomes.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The randomisation schedules will be concealed in sealed envelopes until an investigator designated as a treatment administrator unseals the envelope before the first treatment at Visit 2, following confirmation of eligibility after Visit 1.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A researcher not involved with performing the clinical assessments will develop a randomisation schedule using a randomisation table created by computer software (i.e., computerised sequence generation) for the study intervention (1:1:1), and also a separate randomisation (1:1) sub-schedule for sham red or sham blue light intervention for those sub-randomised to the inactive control therapy group. The randomisation schedules will be concealed in sealed envelopes until a study researcher designated as a treatment administrator unseals the envelope before the first treatment at Visit 2.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Mixed model analysis will be performed for inter-group differences in changes from baseline (Visit 1) to follow-up visits in corneal immune cell morphodynamic feature, tear pro-inflammatory cytokine and chemokine levels, tear rheology, corneal temperatures, and clinical ocular surface measures. Correlation analyses (e.g., Pearson or Spearman, as informed by the data) will be performed for examining the relationship between:
• corneal immune cell features and tear pro-inflammatory cytokine and chemokine levels across all study groups at Visits 3 to 6.
• tear rheology parameters and tear pro-inflammatory cytokine and chemokine levels across all study groups at Visits 3 to 6.
• clinical parameters of dry eye and meibomian gland function measures (OSDI and OSDI-6 scores, TMH, NITBUT, bulbar conjunctival hyperaemia, corneal and conjunctival staining, lid wiper epitheliopathy, lid margin telangiectasia, MGS and MGYLS scores) and corneal immune cell features across all study groups at Visits 3 to 6.
• corneal immune cell features and tear osmolarity across all study groups at Visit 6.
• corneal immune cell features and meibography across all study groups at Visit 6.
• mean temperature and rate of temperature change of the cornea, and corneal immune cell features (at Visit 2).

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321299 0
University
Name [1] 321299 0
The University Of Melbourne
Country [1] 321299 0
Australia
Primary sponsor type
University
Name
The University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 324027 0
None
Name [1] 324027 0
Address [1] 324027 0
Country [1] 324027 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319831 0
Science, Technology, Engineering, Mathematics and Medicine (STEMM 3) – Greater Than Low Risk (GTLR) committee
Ethics committee address [1] 319831 0
Ethics committee country [1] 319831 0
Australia
Date submitted for ethics approval [1] 319831 0
12/05/2026
Approval date [1] 319831 0
26/06/2026
Ethics approval number [1] 319831 0
2026-35637-82232-2

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148546 0
Dr Jeremy Chung Bo Chiang
Address 148546 0
Department of Optometry and Vision Sciences, The University of Melbourne, 200 Berkeley St, Carlton,Victoria, 3053
Country 148546 0
Australia
Phone 148546 0
+613 9035 3043
Fax 148546 0
Email 148546 0
Contact person for public queries
Name 148547 0
Prof Laura Downie
Address 148547 0
Department of Optometry and Vision Sciences, The University of Melbourne, 200 Berkeley St, Carlton,Victoria, 3053
Country 148547 0
Australia
Phone 148547 0
+613 9035 3043
Fax 148547 0
Email 148547 0
Contact person for scientific queries
Name 148548 0
Prof Laura Downie
Address 148548 0
Department of Optometry and Vision Sciences, The University of Melbourne, 200 Berkeley St, Carlton,Victoria, 3053
Country 148548 0
Australia
Phone 148548 0
+613 9035 3043
Fax 148548 0
Email 148548 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.